공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

말초신경병증 치료 시장 : 유형, 치료(약물 요법, 비약물 요법), 유통 채널별, 지역별 - 규모, 점유율, 전망, 기회 분석(2020-2027년)

Peripheral Neuropathy Treatment Market, by Type, by Treatment (Pharmacological Therapies and Non-pharmacological Therapies, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

리서치사 Coherent Market Insights
발행일 2020년 12월 상품 코드 980048
페이지 정보 영문
가격
US $ 4,500 ₩ 5,006,000 PPT Turned PDF (Single User License)
US $ 7,000 ₩ 7,788,000 PPT Turned PDF (Multi-user License)
US $ 10,000 ₩ 11,126,000 PPT Turned PDF (Enterprise User License)


말초신경병증 치료 시장 : 유형, 치료(약물 요법, 비약물 요법), 유통 채널별, 지역별 - 규모, 점유율, 전망, 기회 분석(2020-2027년) Peripheral Neuropathy Treatment Market, by Type, by Treatment (Pharmacological Therapies and Non-pharmacological Therapies, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
발행일 : 2020년 12월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 말초신경병증 치료 시장의 성장요인으로 고령화 인구의 증가를 들 수 있습니다. 2018년 2월에 세계보건기구(WHO)가 발표한 기사에 따르면 2015-2050년 세계 고령 인구의 비율은 12%에서 22%로 거의 배증한다고 보고되고 있습니다. 또한 당뇨병의 증례 증가는 이 시장의 성장을 촉진할 것으로 예상되고 있습니다. 국제당뇨병연맹(IDF)이 발표한 기사에 따르면 2017년 18-99세 당뇨병 환자의 추정수는 세계에서 약 4억 2,500만 명입니다.

세계의 말초신경병증 치료 시장에 대해 조사했으며, 시장 규모 및 점유율, 시장 기회 및 동향, 성장 및 억제요인, 유형·치료·유통 채널·지역별 시장 분석, 경쟁 구도, 주요 기업의 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 조사 목적·전제조건

제2장 시장의 전망

  • 리포트의 개요
    • 시장의 정의와 범위
  • 개요
    • 시장 내역 : 유형별
    • 시장 내역 : 치료별
    • 시장 내역 : 유통 채널별
    • 시장 내역 : 지역별
  • Coherent Opportunity Map(COM)

제3장 시장 역학, 규제 및 동향 분석

  • 시장 역학
    • 성장요인
    • 억제요인
    • 시장 기회
  • 영향 분석
  • 파이프라인 분석
  • 상환 시나리오
  • 역학
  • PEST 분석
  • 규제 시나리오
  • 신제품 발매
  • 협업과 계약
  • 시장 동향

제4장 COVID-19 팬데믹의 영향

  • COVID-19 시장 시나리오
  • COVID-19 시장이 말초신경병증 치료제에 미치는 영향

제5장 시장 분석 : 유형별(2016-2027)

  • 서론
  • 당뇨병성 말초신경병증
  • 화학요법 유발성 말초신경병증
  • 특발성 말초신경병증
  • 기타

제6장 시장 분석 : 치료별(2016-2027)

  • 서론
  • 약물 요법
  • 비약물 요법

제7장 시장 분석 : 유통 채널별(2016-2027)

  • 서론
  • 병원과 클리닉
  • 외래 센터
  • 기타

제8장 시장 분석 : 지역별(2016-2027)

  • 서론
  • 북미
  • 라틴아메리카
  • 유럽
  • 아시아태평양
  • 중동
  • 아프리카

제9장 경쟁 구도

  • 히트맵 분석
  • 시장 점유율 분석
    • Abbott
    • Bristol Myers Squibb
    • Cipla Limited
    • Eli Lilly and Company
    • GlaxoSmithKline plc.
    • Lupin Limited
    • Merck and Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Dr. Reddy's Laboratories
    • Mylan NV
    • Johnson & Johnson Services Inc.
    • Teva Pharmaceutical Industries Ltd.

제10장 애널리스트의 견해

제11장 섹션

KSA 21.01.13

Title:
Peripheral Neuropathy Treatment Market, by Type (Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, and Others), by Treatment (Pharmacological Therapies (Pain Relievers, Anti-seizure Medications, and Antidepressants) and Non-pharmacological Therapies (Transcutaneous Electrical Nerve Stimulation, Plasma Exchange and Intravenous Immune Globulin, and Others), by Distribution Channel (Hospitals and Clinics, Ambulatory Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Peripheral neuropathy is a disorder that affects the peripheral nerves. Peripheral neuropathy has a variety of systemic, metabolic, and toxic causes, for instance diabetes in metabolic cause. The most common treatable causes include diabetes mellitus, hypothyroidism, and nutritional deficiencies. The diagnosis require careful clinical assessment, judicious laboratory testing, and electro diagnostic studies or nerve biopsy, if the diagnosis remains unclear.

Market Dynamics

Rising aging population is expected to drive the global peripheral neuropathy treatment market growth. For instance, according to an article published by the World Health Organization (WHO) in February 2018, reports that between 2015 and 2050, the proportion of the worldwide geriatric population will nearly double from 12% to 22%.

Moreover, rising diabetic cases is expected to drive the market growth. For instance, according to an article published by the International Diabetes Federation (IDF), in 2017, the estimated number of 18 to 99 year old diabetic patients was around 425 million globally.

researched

medicinal properties of cannabis and its derivatives are widely

Researched

Medicinal properties of cannabis and its derivatives are widely

researched

medicinal properties of cannabis and its derivatives are widely

researched

medicinal properties of cannabis and its derivatives are widely

researched

Key features of the study:

  • This report provides in-depth analysis of the global peripheral neuropathy treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global peripheral neuropathy treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Abbott, Bristol Myers Squibb, Cipla Limited, Eli Lilly and Company, GlaxoSmithKline plc., Lupin Limited, Merck and Co. Inc., Novartis AG, Pfizer Inc., Dr. Reddy's Laboratories, Mylan NV, Johnson & Johnson Services Inc., and Teva Pharmaceutical Industries Ltd, among others.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global peripheral neuropathy treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global peripheral neuropathy treatment market.

Detailed Segmentation:

  • Global Peripheral Neuropathy Treatment Market, By Type:
    • Diabetic Peripheral Neuropathy
    • Chemotherapy-induced Peripheral Neuropathy
    • Idiopathic Peripheral Neuropathy
    • Others
  • Global Peripheral Neuropathy Treatment Market, By Treatment:
    • Pharmacological Therapies
      • Pain Relievers
      • Anti-seizure Medications
      • Antidepressants
    • Non-pharmacological Therapies
      • Transcutaneous Electrical Nerve Stimulation
      • Plasma Exchange and Intravenous Immune Globulin
      • Others
  • Global Peripheral Neuropathy Treatment Market, By Distribution Channel:
    • Hospitals and Clinics
    • Ambulatory Centers
    • Others
  • Global Peripheral Neuropathy Treatment Market, By Region:
    • North America
      • By Type:
      • Diabetic Peripheral Neuropathy
      • Chemotherapy-induced Peripheral Neuropathy
      • Idiopathic Peripheral Neuropathy
      • Others
      • By Treatment:
      • Pharmacological Therapies
      • Pain Relievers
      • Anti-seizure Medications
      • Antidepressants
      • Non-pharmacological Therapies
      • Transcutaneous Electrical Nerve Stimulation
      • Plasma Exchange and Intravenous Immune Globulin
      • Others
      • By Distribution Channel:
      • Hospitals and Clinics
      • Ambulatory Centers
      • Others
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Type:
      • Diabetic Peripheral Neuropathy
      • Chemotherapy-induced Peripheral Neuropathy
      • Idiopathic Peripheral Neuropathy
      • Others
      • By Treatment:
      • By Treatment:
      • Pharmacological Therapies
      • Pain Relievers
      • Anti-seizure Medications
      • Antidepressants
      • Non-pharmacological Therapies
      • Transcutaneous Electrical Nerve Stimulation
      • Plasma Exchange and Intravenous Immune Globulin
      • Others
      • By Distribution Channel:
      • Hospitals and Clinics
      • Ambulatory Centers
      • Others
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Type:
      • Diabetic Peripheral Neuropathy
      • Chemotherapy-induced Peripheral Neuropathy
      • Idiopathic Peripheral Neuropathy
      • Others
      • By Treatment:
      • Pharmacological Therapies
      • Pain Relievers
      • Anti-seizure Medications
      • Antidepressants
      • Non-pharmacological Therapies
      • Transcutaneous Electrical Nerve Stimulation
      • Plasma Exchange and Intravenous Immune Globulin
      • Others
      • By Distribution Channel:
      • Hospitals and Clinics
      • Ambulatory Centers
      • Others
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Type:
      • Diabetic Peripheral Neuropathy
      • Chemotherapy-induced Peripheral Neuropathy
      • Idiopathic Peripheral Neuropathy
      • Others
      • By Treatment:
      • Pharmacological Therapies
      • Pain Relievers
      • Anti-seizure Medications
      • Antidepressants
      • Non-pharmacological Therapies
      • Transcutaneous Electrical Nerve Stimulation
      • Plasma Exchange and Intravenous Immune Globulin
      • Others
      • By Distribution Channel:
      • Hospitals and Clinics
      • Ambulatory Centers
      • Others
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Type:
      • Diabetic Peripheral Neuropathy
      • Chemotherapy-induced Peripheral Neuropathy
      • Idiopathic Peripheral Neuropathy
      • Others
      • By Treatment:
      • Pharmacological Therapies
      • Pain Relievers
      • Anti-seizure Medications
      • Antidepressants
      • Non-pharmacological Therapies
      • Transcutaneous Electrical Nerve Stimulation
      • Plasma Exchange and Intravenous Immune Globulin
      • Others
      • By Distribution Channel:
      • Hospitals and Clinics
      • Ambulatory Centers
      • Others
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Type:
      • Diabetic Peripheral Neuropathy
      • Chemotherapy-induced Peripheral Neuropathy
      • Idiopathic Peripheral Neuropathy
      • Others
      • By Treatment:
      • Pharmacological Therapies
      • Pain Relievers
      • Anti-seizure Medications
      • Antidepressants
      • Non-pharmacological Therapies
      • Transcutaneous Electrical Nerve Stimulation
      • Plasma Exchange and Intravenous Immune Globulin
      • Others
      • By Distribution Channel:
      • Hospitals and Clinics
      • Ambulatory Centers
      • Others
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Abbott*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Bristol Myers Squibb
    • Cipla Limited
    • Eli Lilly and Company
    • GlaxoSmithKline plc.
    • Lupin Limited
    • Merck and Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Dr. Reddy's Laboratories
    • Mylan NV
    • Johnson & Johnson Services Inc.
    • Teva Pharmaceutical Industries Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Type
    • Market Snippet, By Treatment
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • Reimbursement Scenario
  • Epidemiology
  • Pest Analysis
  • Regulatory Scenario
  • New Product Launches
  • Collaborations and Agreements
  • Market Trends

4. Global Peripheral Neuropathy Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Market Scenario
  • Impact of COVID-19 Market on the Peripheral Neuropathy Treatment Products

5. Global Peripheral Neuropathy Treatment Market, By Type, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Diabetic Peripheral Neuropathy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Chemotherapy-induced Peripheral Neuropathy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Idiopathic Peripheral Neuropathy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

6. Global Peripheral Neuropathy Treatment Market, By Treatment, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Pharmacological Therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Pain Relievers
    • Anti-seizure Medications
    • Antidepressants
  • Non-pharmacological Therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Transcutaneous Electrical Nerve Stimulation
    • Plasma Exchange and Intravenous Immune Globulin
    • Others

7. Global Peripheral Neuropathy Treatment Market, By Distribution Channel, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospitals and Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Ambulatory Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

8. Global Peripheral Neuropathy Treatment Market, By Region, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2027
  • North America
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

9. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • Abbott
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Bristol Myers Squibb
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Cipla Limited
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • GlaxoSmithKline plc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Lupin Limited
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Merck and Co. Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Dr. Reddy's Laboratories
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Mylan NV
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Johnson & Johnson Services Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies

10. Analyst Views

11. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top
전화 문의
F A Q